Department of Molecular Pathology, Institute of Pathology and Neuropathology, University Hospital of Tuebingen, 72076 Tuebingen, Germany.
Virus Res. 2013 Sep;176(1-2):155-60. doi: 10.1016/j.virusres.2013.05.020. Epub 2013 Jun 13.
Human parvovirus B19 (B19V) has been considered to cause acute and chronic myocarditis, which is accompanied by endothelial dysfunction. Currently, no causative treatment option for B19V-infections is available. Since RNA interference (RNAi) has proven to be a highly potent antiviral approach, the aim of the current study was to develop an RNAi-based strategy to inhibit B19V replication. Three B19V-VP2-specific short hairpin RNAs (shRNAs) were designed and tested for their silencing activity in reporter assays and the expression cassette of the best one was introduced into an adenoviral shuttle vector (Ad5). B19V-permissive UT7/Epo-S1 cells were infected with B19V and the RNAi triggers were delivered by the adenoviral vector (Ad5shVP2) 24h thereafter. The shRNA targeting the B19V-VP2 gene significantly suppressed VP2 mRNA levels as determined by quantitative RT-PCR. Additionally, also the expression levels of the non-targeted non-structural B19V-NS1 mRNA were strongly reduced. Our results demonstrate that vector-mediated delivery of shRNA expression cassettes targeting the structural B19-VP2 gene is a suitable approach to inhibit B19V replication.
人细小病毒 B19(B19V)被认为会引起急性和慢性心肌炎,并伴有内皮功能障碍。目前,尚无针对 B19V 感染的特效治疗方法。由于 RNA 干扰(RNAi)已被证明是一种非常有效的抗病毒方法,因此本研究旨在开发一种基于 RNAi 的策略来抑制 B19V 复制。设计了三种针对 B19V-VP2 的短发夹 RNA(shRNA),并在报告基因检测和最佳表达盒的表达载体中进行了测试。B19V 允许的 UT7/Epo-S1 细胞被 B19V 感染,随后在 24 小时内用腺病毒载体(Ad5shVP2)传递 RNAi 触发物。针对 B19V-VP2 基因的 shRNA 显著抑制了定量 RT-PCR 测定的 VP2 mRNA 水平。此外,非靶向非结构 B19V-NS1 mRNA 的表达水平也被强烈降低。我们的研究结果表明,针对结构 B19-VP2 基因的载体介导的 shRNA 表达盒的递送是抑制 B19V 复制的一种合适方法。